Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response

ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., ...Daha Fazla

TUMORI, cilt.97, sa.6, ss.711-716, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 97 Sayı: 6
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1700/1018.11086
  • Dergi Adı: TUMORI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.711-716
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Aims and background. Capecitabine, as all fluoropyrimidines, interferes with vitamin metabolism and may thus have an impact on hematopoiesis. It is metabolized to its active form 5-fluoruracil by the enzyme thymidine phosphorylase, which exists in higher concentrations in tumor tissue and liver than in normal tissues. In the study, we investigated the changes in mean corpuscular volume (MCV) of red blood cells and the possible correlation of these changes with the clinical outcome of capecitabine treatment in women with metastatic breast cancer.